aTyr Pharma, Inc. (ATYR) 10-Year Financial Performance & Capital Metrics

ATYR • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Show more

Revenue $235K -33.4%
EBITDA -$66M -27.2%
Net Income -$64M -27.1%
EPS (Diluted) -0.86 +8.5%
Gross Margin 100%
EBITDA Margin -28244.26% -91.1%
Operating Margin -28899.57% -85.8%
Net Margin -27243.83% -90.9%
ROE -79.88% -28.2%
ROIC -65.69% -24.3%
Debt/Equity 0.19 +14.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Sales declining 11.0% over 5 years
✗Shares diluted 38.5% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-11.05%

3Y-

TTM-19.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM11.7%

ROCE

10Y Avg-60.92%

5Y Avg-56.99%

3Y Avg-60.16%

Latest-72.99%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	422K	10.46M	0	10.39M	353K	235K
Revenue Growth %	-	-	-	-	-	23.77%	-1%	-	-0.97%	-0.33%
Cost of Goods Sold+	0	900K	713K	746K	14.05M	17.29M	1.3M	1.7M	0	0
COGS % of Revenue	-	-	-	-	33.29%	1.65%	-	0.16%	-	-
Gross Profit+	0	-900K	-713K	-746K	-13.63M	-6.84M	-1.3M	8.69M	353K	235K
Gross Margin %	-	-	-	-	-32.29%	-0.65%	-	0.84%	1%	1%
Gross Profit Growth %	-	-	0.21%	-0.05%	-17.27%	0.5%	0.81%	7.66%	-0.96%	-0.33%
Operating Expenses+	47.62M	58.44M	46.43M	32.07M	9.35M	9.07M	32.71M	55.09M	55.27M	68.15M
OpEx % of Revenue	-	-	-	-	22.16%	0.87%	-	5.3%	156.58%	290%
Selling, General & Admin	13.11M	14.19M	16.36M	11.69M	9.35M	9.07M	10.75M	12.29M	12.98M	13.78M
SG&A % of Revenue	-	-	-	-	22.16%	0.87%	-	1.18%	36.77%	58.63%
Research & Development	34.5M	44.25M	30.07M	20.39M	14.05M	17.29M	23.26M	42.81M	42.29M	54.37M
R&D % of Revenue	-	-	-	-	33.29%	1.65%	-	4.12%	119.81%	231.37%
Other Operating Expenses	0	0	0	0	-14.05M	-17.29M	-1.3M	0	0	0
Operating Income+	-47.62M	-59.34M	-47.15M	-32.82M	-22.98M	-15.91M	-34.02M	-46.4M	-54.92M	-67.91M
Operating Margin %	-	-	-	-	-54.45%	-1.52%	-	-4.47%	-155.58%	-289%
Operating Income Growth %	-1.02%	-0.25%	0.21%	0.3%	0.3%	0.31%	-1.14%	-0.36%	-0.18%	-0.24%
EBITDA+	-46.75M	-58.44M	-46.43M	-32.07M	-22.34M	-14.64M	-32.71M	-44.71M	-52.18M	-66.37M
EBITDA Margin %	-	-	-	-	-52.95%	-1.4%	-	-4.3%	-147.81%	-282.44%
EBITDA Growth %	-1.06%	-0.25%	0.21%	0.31%	0.3%	0.34%	-1.23%	-0.37%	-0.17%	-0.27%
D&A (Non-Cash Add-back)	869K	900K	713K	746K	635K	1.27M	1.3M	1.7M	2.74M	1.54M
EBIT	-46.22M	-57.94M	-47.15M	-34.52M	-22.98M	-15.91M	-33.78M	-46.4M	-54.92M	-67.91M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	65K	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-357K	1.44M	-1.06M	-1.7M	-785K	-319K	238K	1.06M	4.52M	3.89M
Pretax Income+	-47.97M	-57.9M	-48.21M	-34.52M	-23.76M	-16.23M	-33.78M	-45.34M	-50.4M	-64.02M
Pretax Margin %	-	-	-	-	-56.31%	-1.55%	-	-4.37%	-142.77%	-272.43%
Income Tax+	0	-49K	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.99%	1%	1%	1%	1%	1%
Net Income+	-47.97M	-57.85M	-48.21M	-34.52M	-23.6M	-16.22M	-33.77M	-45.34M	-50.39M	-64.02M
Net Margin %	-	-	-	-	-55.93%	-1.55%	-	-4.37%	-142.75%	-272.44%
Net Income Growth %	-0.97%	-0.21%	0.17%	0.28%	0.32%	0.31%	-1.08%	-0.34%	-0.11%	-0.27%
Net Income (Continuing)	-47.97M	-57.85M	-48.21M	-34.52M	-23.76M	-16.23M	-33.78M	-45.34M	-50.4M	-64.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	-160K	-166K	-175K	-180K	-188K	-187K
EPS (Diluted)+	-42.42	-34.20	-26.16	-16.13	-7.03	-1.77	-1.77	-1.60	-0.94	-0.86
EPS Growth %	0.9%	0.19%	0.24%	0.38%	0.56%	0.75%	0%	0.1%	0.41%	0.09%
EPS (Basic)	-42.42	-34.20	-26.16	-16.13	-7.03	-1.77	-1.77	-1.60	-0.94	-0.86
Diluted Shares Outstanding	1.13M	1.69M	1.84M	2.14M	3.36M	9.16M	19.08M	28.42M	53.61M	74.26M
Basic Shares Outstanding	1.13M	1.69M	1.84M	2.14M	3.36M	9.16M	19.08M	28.42M	53.61M	74.26M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	97.95M	74.77M	86.98M	50.8M	31.93M	35.53M	113.57M	80.87M	102.99M	81.95M
Cash & Short-Term Investments	95.53M	72.15M	85.12M	49.55M	31.14M	31.69M	107.91M	66.15M	98.17M	72.13M
Cash Only	53.02M	38.39M	21.09M	22.96M	9.21M	16.95M	2.34M	9.98M	22.54M	11.05M
Short-Term Investments	42.51M	33.76M	64.03M	26.58M	21.93M	14.74M	105.58M	56.16M	75.62M	61.07M
Accounts Receivable	0	0	0	0	100K	2.04M	435K	11.78M	2.44M	1.74M
Days Sales Outstanding	-	-	-	-	86.49	71.18	-	413.81	2.52K	2.7K
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	31.73M	5.76M	2.37M	1.94M	4.26M	3.19M	1.97M	14.91M	17.66M	14.88M
Property, Plant & Equipment	1.79M	1.42M	2.28M	1.85M	4.09M	2.98M	1.81M	11.56M	14.05M	11.86M
Fixed Asset Turnover	-	-	-	-	0.10x	3.51x	-	0.90x	0.03x	0.02x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	29.81M	4M	0	0	0	0	0	0	0	0
Other Non-Current Assets	118K	333K	90K	90K	172K	213K	158K	3.36M	3.62M	3.02M
Total Assets+	129.68M	80.52M	89.36M	52.75M	36.19M	38.73M	115.54M	95.79M	120.65M	96.83M
Asset Turnover	-	-	-	-	0.01x	0.27x	-	0.11x	0.00x	0.00x
Asset Growth %	5.28%	-0.38%	0.11%	-0.41%	-0.31%	0.07%	1.98%	-0.17%	0.26%	-0.2%
Total Current Liabilities+	12.15M	8.53M	10.39M	10.83M	12.92M	5.86M	6.01M	13.86M	16.42M	14.97M
Accounts Payable	3.87M	2.61M	2.28M	1.04M	847K	1.43M	1.03M	3.11M	3.53M	4.32M
Days Payables Outstanding	-	1.06K	1.17K	508.85	22.01	30.21	288.59	668.84	-	-
Short-Term Debt	3.37M	339K	5.01M	7.77M	8.74M	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	208K	0	0	0	0	0
Other Current Liabilities	315K	130K	0	0	0	0	0	0	0	0
Current Ratio	8.06x	8.77x	8.37x	4.69x	2.47x	6.06x	18.89x	5.83x	6.27x	5.48x
Quick Ratio	8.06x	8.77x	8.37x	4.69x	2.47x	6.06x	18.89x	5.83x	6.27x	5.48x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.48M	9.2M	14.72M	8.26M	2.24M	1.38M	398K	10.64M	13.77M	12.03M
Long-Term Debt	1.78M	9.2M	14.72M	8.26M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.24M	1.38M	398K	10.64M	13.77M	12.03M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	701K	0	0	0	0	0	0	0	0	0
Total Liabilities	14.63M	17.72M	25.11M	19.1M	15.16M	7.24M	6.41M	24.5M	30.18M	27M
Total Debt+	5.14M	9.54M	19.73M	16.03M	11.73M	2.24M	1.38M	11.53M	15.1M	13.28M
Net Debt	-47.88M	-28.85M	-1.36M	-6.93M	2.52M	-14.71M	-958K	1.55M	-7.45M	2.23M
Debt / Equity	0.04x	0.15x	0.31x	0.48x	0.56x	0.07x	0.01x	0.16x	0.17x	0.19x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	115.05M	62.8M	64.25M	33.65M	21.03M	31.48M	109.13M	71.28M	90.47M	69.83M
Equity Growth %	2.26%	-0.45%	0.02%	-0.48%	-0.38%	0.5%	2.47%	-0.35%	0.27%	-0.23%
Book Value per Share	101.70	37.13	34.86	15.73	6.27	3.44	5.72	2.51	1.69	0.94
Total Shareholders' Equity	115.05M	62.8M	64.25M	33.65M	21.19M	31.65M	109.3M	71.46M	90.66M	70.02M
Common Stock	24K	24K	30K	31K	4K	11K	28K	29K	63K	84K
Retained Earnings	-158.12M	-215.98M	-264.19M	-298.7M	-322.3M	-338.53M	-372.3M	-417.63M	-468.02M	-532.05M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-171K	-76K	-120K	-60K	-40K	-43K	-263K	-433K	-74K	-40K
Minority Interest	0	0	0	0	-160K	-166K	-175K	-180K	-188K	-187K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-36.8M	-52.86M	-42.36M	-31.06M	-20.01M	-15.3M	-33.08M	-41.89M	-33.22M	-69.12M
Operating CF Margin %	-	-	-	-	-47.42%	-1.46%	-	-4.03%	-94.11%	-294.12%
Operating CF Growth %	-0.61%	-0.44%	0.2%	0.27%	0.36%	0.24%	-1.16%	-0.27%	0.21%	-1.08%
Net Income	-47.97M	-57.85M	-48.21M	-34.52M	-23.76M	-16.22M	-33.77M	-45.34M	-50.39M	-64.02M
Depreciation & Amortization	869K	900K	713K	746K	1.37M	1.27M	1.3M	1.7M	2.74M	1.54M
Stock-Based Compensation	4.86M	0	0	0	1.78M	1.47M	1.61M	2.15M	2.6M	2.99M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	2.17M	7.25M	10.78M	7.7M	395K	453K	363K	441K	-3.19M	-2.71M
Working Capital Changes	3.28M	-1.35M	-1.73M	-1.45M	206K	-2.26M	-2.59M	-833K	15.01M	-6.92M
Change in Receivables	0	0	0	0	58K	-1.94M	1.6M	-11.92M	9.05M	402K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	-2.49M	-2.06M	0	1.76M	47K	0	3.26M	-1.34M
Cash from Investing+	-71.99M	33.53M	-27.64M	37.17M	4.92M	6.9M	-91.57M	47.24M	-20.13M	17.23M
Capital Expenditures	-664K	-600K	-1.31M	-594K	-79K	-202K	-192K	-1.64M	-4.21M	-65K
CapEx % of Revenue	-	-	-	-	0.19%	0.02%	-	0.16%	11.94%	0.28%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	51K	0	0	179K	15K	0
Cash from Financing+	147.92M	4.7M	52.7M	-4.24M	1.34M	16.14M	110.03M	5.45M	66.23M	39.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	163K	361K	50K	13K	10K	73K	45K	105K	100K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-37.46M	-53.46M	-43.68M	-31.66M	-20.09M	-15.5M	-33.27M	-43.53M	-37.44M	-69.18M
FCF Margin %	-	-	-	-	-47.61%	-1.48%	-	-4.19%	-106.05%	-294.4%
FCF Growth %	-0.62%	-0.43%	0.18%	0.28%	0.37%	0.23%	-1.15%	-0.31%	0.14%	-0.85%
FCF per Share	-33.11	-31.61	-23.70	-14.79	-5.99	-1.69	-1.74	-1.53	-0.70	-0.93
FCF Conversion (FCF/Net Income)	0.77x	0.91x	0.88x	0.90x	0.85x	0.94x	0.98x	0.92x	0.66x	1.08x
Interest Paid	925K	0	0	0	1.12M	0	0	54K	0	137K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-399.11%	-65.06%	-75.89%	-70.51%	-86.34%	-61.79%	-48.03%	-50.26%	-62.3%	-79.88%
Return on Invested Capital (ROIC)	-	-88.03%	-73.03%	-54.94%	-68.57%	-59.2%	-40.84%	-38.46%	-52.85%	-65.69%
Gross Margin	-	-	-	-	-3228.91%	-65.39%	-	83.68%	100%	100%
Net Margin	-	-	-	-	-5593.13%	-155.18%	-	-436.53%	-14274.5%	-27243.83%
Debt / Equity	0.04x	0.15x	0.31x	0.48x	0.56x	0.07x	0.01x	0.16x	0.17x	0.19x
FCF Conversion	0.77x	0.91x	0.88x	0.90x	0.85x	0.94x	0.98x	0.92x	0.66x	1.08x
Revenue Growth	-	-	-	-	-	2377.49%	-100%	-	-96.6%	-33.43%

Frequently Asked Questions

Growth & Financials

aTyr Pharma, Inc. (ATYR) reported $0.2M in revenue for fiscal year 2024.

aTyr Pharma, Inc. (ATYR) saw revenue decline by 33.4% over the past year.

aTyr Pharma, Inc. (ATYR) reported a net loss of $75.1M for fiscal year 2024.

Dividend & Returns

aTyr Pharma, Inc. (ATYR) has a return on equity (ROE) of -79.9%. Negative ROE indicates the company is unprofitable.

aTyr Pharma, Inc. (ATYR) had negative free cash flow of $63.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

aTyr Pharma, Inc. (ATYR) 10-Year Financial Performance & Capital Metrics

ATYR • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $235K -33.4%
EBITDA -$66M -27.2%
Net Income -$64M -27.1%
EPS (Diluted) -0.86 +8.5%
Gross Margin 100%
EBITDA Margin -28244.26% -91.1%
Operating Margin -28899.57% -85.8%
Net Margin -27243.83% -90.9%
ROE -79.88% -28.2%
ROIC -65.69% -24.3%
Debt/Equity 0.19 +14.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Sales declining 11.0% over 5 years
✗Shares diluted 38.5% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-11.05%

3Y-

TTM-19.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM11.7%

ROCE

10Y Avg-60.92%

5Y Avg-56.99%

3Y Avg-60.16%

Latest-72.99%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	422K	10.46M	0	10.39M	353K	235K
Revenue Growth %	-	-	-	-	-	23.77%	-1%	-	-0.97%	-0.33%
Cost of Goods Sold+	0	900K	713K	746K	14.05M	17.29M	1.3M	1.7M	0	0
COGS % of Revenue	-	-	-	-	33.29%	1.65%	-	0.16%	-	-
Gross Profit+	0	-900K	-713K	-746K	-13.63M	-6.84M	-1.3M	8.69M	353K	235K
Gross Margin %	-	-	-	-	-32.29%	-0.65%	-	0.84%	1%	1%
Gross Profit Growth %	-	-	0.21%	-0.05%	-17.27%	0.5%	0.81%	7.66%	-0.96%	-0.33%
Operating Expenses+	47.62M	58.44M	46.43M	32.07M	9.35M	9.07M	32.71M	55.09M	55.27M	68.15M
OpEx % of Revenue	-	-	-	-	22.16%	0.87%	-	5.3%	156.58%	290%
Selling, General & Admin	13.11M	14.19M	16.36M	11.69M	9.35M	9.07M	10.75M	12.29M	12.98M	13.78M
SG&A % of Revenue	-	-	-	-	22.16%	0.87%	-	1.18%	36.77%	58.63%
Research & Development	34.5M	44.25M	30.07M	20.39M	14.05M	17.29M	23.26M	42.81M	42.29M	54.37M
R&D % of Revenue	-	-	-	-	33.29%	1.65%	-	4.12%	119.81%	231.37%
Other Operating Expenses	0	0	0	0	-14.05M	-17.29M	-1.3M	0	0	0
Operating Income+	-47.62M	-59.34M	-47.15M	-32.82M	-22.98M	-15.91M	-34.02M	-46.4M	-54.92M	-67.91M
Operating Margin %	-	-	-	-	-54.45%	-1.52%	-	-4.47%	-155.58%	-289%
Operating Income Growth %	-1.02%	-0.25%	0.21%	0.3%	0.3%	0.31%	-1.14%	-0.36%	-0.18%	-0.24%
EBITDA+	-46.75M	-58.44M	-46.43M	-32.07M	-22.34M	-14.64M	-32.71M	-44.71M	-52.18M	-66.37M
EBITDA Margin %	-	-	-	-	-52.95%	-1.4%	-	-4.3%	-147.81%	-282.44%
EBITDA Growth %	-1.06%	-0.25%	0.21%	0.31%	0.3%	0.34%	-1.23%	-0.37%	-0.17%	-0.27%
D&A (Non-Cash Add-back)	869K	900K	713K	746K	635K	1.27M	1.3M	1.7M	2.74M	1.54M
EBIT	-46.22M	-57.94M	-47.15M	-34.52M	-22.98M	-15.91M	-33.78M	-46.4M	-54.92M	-67.91M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	65K	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-357K	1.44M	-1.06M	-1.7M	-785K	-319K	238K	1.06M	4.52M	3.89M
Pretax Income+	-47.97M	-57.9M	-48.21M	-34.52M	-23.76M	-16.23M	-33.78M	-45.34M	-50.4M	-64.02M
Pretax Margin %	-	-	-	-	-56.31%	-1.55%	-	-4.37%	-142.77%	-272.43%
Income Tax+	0	-49K	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.99%	1%	1%	1%	1%	1%
Net Income+	-47.97M	-57.85M	-48.21M	-34.52M	-23.6M	-16.22M	-33.77M	-45.34M	-50.39M	-64.02M
Net Margin %	-	-	-	-	-55.93%	-1.55%	-	-4.37%	-142.75%	-272.44%
Net Income Growth %	-0.97%	-0.21%	0.17%	0.28%	0.32%	0.31%	-1.08%	-0.34%	-0.11%	-0.27%
Net Income (Continuing)	-47.97M	-57.85M	-48.21M	-34.52M	-23.76M	-16.23M	-33.78M	-45.34M	-50.4M	-64.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	-160K	-166K	-175K	-180K	-188K	-187K
EPS (Diluted)+	-42.42	-34.20	-26.16	-16.13	-7.03	-1.77	-1.77	-1.60	-0.94	-0.86
EPS Growth %	0.9%	0.19%	0.24%	0.38%	0.56%	0.75%	0%	0.1%	0.41%	0.09%
EPS (Basic)	-42.42	-34.20	-26.16	-16.13	-7.03	-1.77	-1.77	-1.60	-0.94	-0.86
Diluted Shares Outstanding	1.13M	1.69M	1.84M	2.14M	3.36M	9.16M	19.08M	28.42M	53.61M	74.26M
Basic Shares Outstanding	1.13M	1.69M	1.84M	2.14M	3.36M	9.16M	19.08M	28.42M	53.61M	74.26M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	97.95M	74.77M	86.98M	50.8M	31.93M	35.53M	113.57M	80.87M	102.99M	81.95M
Cash & Short-Term Investments	95.53M	72.15M	85.12M	49.55M	31.14M	31.69M	107.91M	66.15M	98.17M	72.13M
Cash Only	53.02M	38.39M	21.09M	22.96M	9.21M	16.95M	2.34M	9.98M	22.54M	11.05M
Short-Term Investments	42.51M	33.76M	64.03M	26.58M	21.93M	14.74M	105.58M	56.16M	75.62M	61.07M
Accounts Receivable	0	0	0	0	100K	2.04M	435K	11.78M	2.44M	1.74M
Days Sales Outstanding	-	-	-	-	86.49	71.18	-	413.81	2.52K	2.7K
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	31.73M	5.76M	2.37M	1.94M	4.26M	3.19M	1.97M	14.91M	17.66M	14.88M
Property, Plant & Equipment	1.79M	1.42M	2.28M	1.85M	4.09M	2.98M	1.81M	11.56M	14.05M	11.86M
Fixed Asset Turnover	-	-	-	-	0.10x	3.51x	-	0.90x	0.03x	0.02x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	29.81M	4M	0	0	0	0	0	0	0	0
Other Non-Current Assets	118K	333K	90K	90K	172K	213K	158K	3.36M	3.62M	3.02M
Total Assets+	129.68M	80.52M	89.36M	52.75M	36.19M	38.73M	115.54M	95.79M	120.65M	96.83M
Asset Turnover	-	-	-	-	0.01x	0.27x	-	0.11x	0.00x	0.00x
Asset Growth %	5.28%	-0.38%	0.11%	-0.41%	-0.31%	0.07%	1.98%	-0.17%	0.26%	-0.2%
Total Current Liabilities+	12.15M	8.53M	10.39M	10.83M	12.92M	5.86M	6.01M	13.86M	16.42M	14.97M
Accounts Payable	3.87M	2.61M	2.28M	1.04M	847K	1.43M	1.03M	3.11M	3.53M	4.32M
Days Payables Outstanding	-	1.06K	1.17K	508.85	22.01	30.21	288.59	668.84	-	-
Short-Term Debt	3.37M	339K	5.01M	7.77M	8.74M	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	208K	0	0	0	0	0
Other Current Liabilities	315K	130K	0	0	0	0	0	0	0	0
Current Ratio	8.06x	8.77x	8.37x	4.69x	2.47x	6.06x	18.89x	5.83x	6.27x	5.48x
Quick Ratio	8.06x	8.77x	8.37x	4.69x	2.47x	6.06x	18.89x	5.83x	6.27x	5.48x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.48M	9.2M	14.72M	8.26M	2.24M	1.38M	398K	10.64M	13.77M	12.03M
Long-Term Debt	1.78M	9.2M	14.72M	8.26M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.24M	1.38M	398K	10.64M	13.77M	12.03M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	701K	0	0	0	0	0	0	0	0	0
Total Liabilities	14.63M	17.72M	25.11M	19.1M	15.16M	7.24M	6.41M	24.5M	30.18M	27M
Total Debt+	5.14M	9.54M	19.73M	16.03M	11.73M	2.24M	1.38M	11.53M	15.1M	13.28M
Net Debt	-47.88M	-28.85M	-1.36M	-6.93M	2.52M	-14.71M	-958K	1.55M	-7.45M	2.23M
Debt / Equity	0.04x	0.15x	0.31x	0.48x	0.56x	0.07x	0.01x	0.16x	0.17x	0.19x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	115.05M	62.8M	64.25M	33.65M	21.03M	31.48M	109.13M	71.28M	90.47M	69.83M
Equity Growth %	2.26%	-0.45%	0.02%	-0.48%	-0.38%	0.5%	2.47%	-0.35%	0.27%	-0.23%
Book Value per Share	101.70	37.13	34.86	15.73	6.27	3.44	5.72	2.51	1.69	0.94
Total Shareholders' Equity	115.05M	62.8M	64.25M	33.65M	21.19M	31.65M	109.3M	71.46M	90.66M	70.02M
Common Stock	24K	24K	30K	31K	4K	11K	28K	29K	63K	84K
Retained Earnings	-158.12M	-215.98M	-264.19M	-298.7M	-322.3M	-338.53M	-372.3M	-417.63M	-468.02M	-532.05M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-171K	-76K	-120K	-60K	-40K	-43K	-263K	-433K	-74K	-40K
Minority Interest	0	0	0	0	-160K	-166K	-175K	-180K	-188K	-187K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-36.8M	-52.86M	-42.36M	-31.06M	-20.01M	-15.3M	-33.08M	-41.89M	-33.22M	-69.12M
Operating CF Margin %	-	-	-	-	-47.42%	-1.46%	-	-4.03%	-94.11%	-294.12%
Operating CF Growth %	-0.61%	-0.44%	0.2%	0.27%	0.36%	0.24%	-1.16%	-0.27%	0.21%	-1.08%
Net Income	-47.97M	-57.85M	-48.21M	-34.52M	-23.76M	-16.22M	-33.77M	-45.34M	-50.39M	-64.02M
Depreciation & Amortization	869K	900K	713K	746K	1.37M	1.27M	1.3M	1.7M	2.74M	1.54M
Stock-Based Compensation	4.86M	0	0	0	1.78M	1.47M	1.61M	2.15M	2.6M	2.99M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	2.17M	7.25M	10.78M	7.7M	395K	453K	363K	441K	-3.19M	-2.71M
Working Capital Changes	3.28M	-1.35M	-1.73M	-1.45M	206K	-2.26M	-2.59M	-833K	15.01M	-6.92M
Change in Receivables	0	0	0	0	58K	-1.94M	1.6M	-11.92M	9.05M	402K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	-2.49M	-2.06M	0	1.76M	47K	0	3.26M	-1.34M
Cash from Investing+	-71.99M	33.53M	-27.64M	37.17M	4.92M	6.9M	-91.57M	47.24M	-20.13M	17.23M
Capital Expenditures	-664K	-600K	-1.31M	-594K	-79K	-202K	-192K	-1.64M	-4.21M	-65K
CapEx % of Revenue	-	-	-	-	0.19%	0.02%	-	0.16%	11.94%	0.28%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	51K	0	0	179K	15K	0
Cash from Financing+	147.92M	4.7M	52.7M	-4.24M	1.34M	16.14M	110.03M	5.45M	66.23M	39.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	163K	361K	50K	13K	10K	73K	45K	105K	100K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-37.46M	-53.46M	-43.68M	-31.66M	-20.09M	-15.5M	-33.27M	-43.53M	-37.44M	-69.18M
FCF Margin %	-	-	-	-	-47.61%	-1.48%	-	-4.19%	-106.05%	-294.4%
FCF Growth %	-0.62%	-0.43%	0.18%	0.28%	0.37%	0.23%	-1.15%	-0.31%	0.14%	-0.85%
FCF per Share	-33.11	-31.61	-23.70	-14.79	-5.99	-1.69	-1.74	-1.53	-0.70	-0.93
FCF Conversion (FCF/Net Income)	0.77x	0.91x	0.88x	0.90x	0.85x	0.94x	0.98x	0.92x	0.66x	1.08x
Interest Paid	925K	0	0	0	1.12M	0	0	54K	0	137K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-399.11%	-65.06%	-75.89%	-70.51%	-86.34%	-61.79%	-48.03%	-50.26%	-62.3%	-79.88%
Return on Invested Capital (ROIC)	-	-88.03%	-73.03%	-54.94%	-68.57%	-59.2%	-40.84%	-38.46%	-52.85%	-65.69%
Gross Margin	-	-	-	-	-3228.91%	-65.39%	-	83.68%	100%	100%
Net Margin	-	-	-	-	-5593.13%	-155.18%	-	-436.53%	-14274.5%	-27243.83%
Debt / Equity	0.04x	0.15x	0.31x	0.48x	0.56x	0.07x	0.01x	0.16x	0.17x	0.19x
FCF Conversion	0.77x	0.91x	0.88x	0.90x	0.85x	0.94x	0.98x	0.92x	0.66x	1.08x
Revenue Growth	-	-	-	-	-	2377.49%	-100%	-	-96.6%	-33.43%

Frequently Asked Questions

Growth & Financials

aTyr Pharma, Inc. (ATYR) reported $0.2M in revenue for fiscal year 2024.

aTyr Pharma, Inc. (ATYR) saw revenue decline by 33.4% over the past year.

aTyr Pharma, Inc. (ATYR) reported a net loss of $75.1M for fiscal year 2024.

Dividend & Returns

aTyr Pharma, Inc. (ATYR) has a return on equity (ROE) of -79.9%. Negative ROE indicates the company is unprofitable.

aTyr Pharma, Inc. (ATYR) had negative free cash flow of $63.0M in fiscal year 2024, likely due to heavy capital investments.